BiotechTube
Home/Ajax Therapeutics/David P. Steensma, MD, FACP
DP

David P. Steensma, MD, FACP

Chief Medical Officer

Ajax Therapeutics

Therapeutic Areas

Hematologic CancersMyeloproliferative NeoplasmsMyelofibrosis

Ajax Therapeutics Pipeline

DrugIndicationPhase
AJ1-11095Myelofibrosis (Primary, Post-Polycythemia Vera, Post-Essential Thrombocythemia)Phase 1

Leadership Team at Ajax Therapeutics

MV
Martin Vogelbaum
Chief Executive Officer, Co-founder
View full Ajax Therapeutics profile